Switching to infliximab biosimilar may lead to more ocular flares in for non-infectious uveitis
Switching from infliximab to a biosimilar infliximab-abda for non-infectious uveitis may lead to more ocular flares, according to a study published in the American Journal of Ophthalmology.
In this retrospective case series, 17 patients with non-infectious uveitis who were switched from originator infliximab to biosimilar infliximab-abda for non-medical reasons, were included.
More ocular flares per person-years were experienced after switching to infliximab-abda (0.92) than with the originator infliximab (0.19, P = 0.028).
Of the 6 patients who experienced flares after switching to infliximab-abda, 66.7% occurred within 90 days of switching. A single patient who flared on originator infliximab went on to develop a single flare on infliximab-abda.
The study authors cautioned provider to monitor patient closely for the first 90 days after switching to infliximab biosimilar.
Deaner JD, Srivastave SK, Hajj-Ali RA, et al. Recurrence rates of inflammation after switching from originator infliximab to biosimilar infliximab-abda for non-infectious uveitis. Am J Ophthalmol. 2020; DOI:https://doi.org/10.1016/j.ajo.2020.08.005.